Semaglutide ndiwopanga glucagon-ngati peptide-1 (GLP-1) receptor agonist, wopangidwa kuti azichiza matenda amtundu wa 2 komanso kunenepa kwambiri. Zosinthidwa mwadongosolo kuti zithetse kuwonongeka kwa enzymatic ndi kupititsa patsogolo theka la moyo, Semaglutide imalola kuti pakhale dosing kamodzi pamlungu, kupititsa patsogolo kwambiri kutsata kwa odwala.
ZathuSemaglutide APIamapangidwa kudzera m'njira yopangidwa mokwanira, ndikuchotsa zoopsa zomwe zimagwirizanitsidwa ndi machitidwe achilengedwe, monga mapuloteni a cell kapena kuipitsidwa kwa DNA. Njira yonse yopangira idapangidwa ndikutsimikiziridwa pamlingo wa kilogalamu, ikukwaniritsa zofunikira zomwe zafotokozeredwa mu chitsogozo cha FDA cha 2021 cha ANDA chopereka mankhwala opangidwa ndi peptide apamwamba kwambiri.
Semaglutide imatsanzira GLP-1 yamunthu, mahomoni a incretin omwe amagwira ntchito yofunika kwambiri pakupanga glucose metabolism. Zimagwira ntchito pogwiritsa ntchito njira zingapo za synergistic:
Imalimbikitsa katulutsidwe ka insulinm'njira yodalira glucose
Imachepetsa katulutsidwe ka glucagon, kuchepetsa kutulutsa kwa glucose m'chiwindi
Imachedwa kutuluka m'mimba, zomwe zimabweretsa kuwongolera kwa glycemic kwa postprandial
Amachepetsa chilakolako cha kudya ndi kudya mphamvu, kuthandizira kuchepa thupi
Maphunziro ochuluka azachipatala (mwachitsanzo, mayesero a SUSTAIN ndi STEP) asonyeza kuti Semaglutide:
Amachepetsa kwambiri HbA1c komanso kusala shuga wa plasma mwa odwala omwe ali ndi matenda amtundu wa 2
Imalimbikitsa kuonda kwakukulu komanso kosalekeza mwa anthu onenepa kwambiri kapena onenepa kwambiri
Amachepetsa zizindikiro za chiopsezo cha mtima monga kuthamanga kwa magazi ndi kutupa
Ndi mbiri yabwino yachitetezo komanso zabwino zambiri zama metabolic, Semaglutide yakhala mzere woyamba wa GLP-1 RA pa matenda a shuga komanso chithandizo chothana ndi kunenepa kwambiri. Mtundu wathu wa API umasunga kukhulupirika kwadongosolo komanso milingo yotsika yonyansa (≤0.1% zonyansa zosadziwika ndi HPLC), kuwonetsetsa kusasinthika kwamankhwala.